FDA Approves Amgen Drug for Extensive Stage Lung Cancer
The drug achieved a 40% response rate in clinical trials for extensive-stage small cell lung cancer with progression after chemotherapy.
The drug achieved a 40% response rate in clinical trials for extensive-stage small cell lung cancer with progression after chemotherapy.